Email updates

Keep up to date with the latest news and content from Arthritis Research & Therapy and BioMed Central.

This article is part of the supplement: 25th European Workshop for Rheumatology Research

Poster presentation

Two-year follow-up results after re-administration of etanercept in active ankylosing spondylitis

X Baraliakos1, J Brandt1, J Listing2, H Haibel3, HM Rudwaleit3, J Sieper3 and J Braun13

Author Affiliations

1 Rheumazentrum Ruhrgebiet, Herne, Germany

2 German Rheumatism Research Center, Epidemiology Department, Berlin, Germany

3 Department of Gastroenterology/Rheumatology, Charité, Medical University Berlin, Campus Benjamin Franklin, Germany

For all author emails, please log on.

Arthritis Research & Therapy 2005, 7(Suppl 1):P28  doi:10.1186/ar1549

The electronic version of this article is the complete one and can be found online at:


Received:11 January 2005
Published:17 February 2005

© 2005 BioMed Central Ltd

Objectives

The tumor necrosis factor alpha (TNF-α) receptor fusion protein etanercept has proven short-term efficacy in patients with active ankylosing spondylitis (AS). The results of continuous treatment with etanercept over 1 year were reported previously. Here we report the experience with the second year of follow-up.

Methods

Overall, 23 out of 30 AS patients (77%) who had participated in the initial placebo-controlled phase of the trial were included in this 2-year extension, where patients with active disease were treated with etanercept (2 × 25 mg subcutaneously twice a week). Disease-modifying anti-rheumatic drugs and steroids were not allowed. The clinical response was assessed by standard assessment tools for disease activity (Bath AS Disease Activity Index [BASDAI]), function (Bath AS Functional Index) and mobility (Bath AS Metrology Index). The primary outcome of this trial was efficacy on disease activity after 2 years of continuous treatment with etanercept in AS patients, compared with patient status at baseline (BL).

Results

Of the 30 initial patients, 21 (70%) completed year 2. At week 102, 54% of the patients had maintained a 50% improvement of BASDAI, and 9/21 (43%) were in a state of partial remission according to the ASAS criteria. The mean BASDAI score remained stable (2.6 ± 2.2 at week 54 and 2.7 ± 2.4 at week 102) in the second study year. Similarly, all other clinical parameters showed no change during year 2 with significant improvement compared with BL. Two patients experienced serious adverse events leading to discontinuation of therapy.

Conclusions

This study confirms the efficacy and safety of etanercept in the therapy of patients with active AS without simultaneous administration of disease-modifying anti-rheumatic drugs or steroids over 2 years of continuous treatment.